STOCK TITAN

[424B5] I-MAB American Prospectus Supplement (Debt Securities)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
424B5
Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. (MLYS) has filed a Form 144 indicating a planned sale of 15,884 common shares through broker Merrill Lynch. Based on the stated aggregate market value, the transaction is valued at approximately $230,430. The shares were acquired on 07/10/2025 via the vesting of a restricted stock unit award granted under the company’s equity-compensation plan and are expected to be sold on or after 07/11/2025 on the NASDAQ.

The filing shows 65,175,287 shares outstanding; the proposed sale therefore represents roughly 0.02 % of total shares. No other sales by the filer have occurred in the past three months, and no material adverse information was asserted in the certification section.

Mineralys Therapeutics, Inc. (MLYS) ha presentato un modulo 144 indicando la prevista vendita di 15.884 azioni ordinarie tramite il broker Merrill Lynch. In base al valore di mercato complessivo dichiarato, l’operazione è valutata approssimativamente 230.430 $. Le azioni sono state acquisite il 10/07/2025 tramite la maturazione di un premio in azioni vincolate concesso nell’ambito del piano di compensazione azionaria della società e si prevede che vengano vendute il o dopo il 11/07/2025 sul NASDAQ.

La comunicazione riporta 65.175.287 azioni in circolazione; la vendita proposta rappresenta quindi circa lo 0,02 % del totale delle azioni. Negli ultimi tre mesi non sono state effettuate altre vendite da parte del dichiarante e nella sezione di certificazione non sono state riportate informazioni negative rilevanti.

Mineralys Therapeutics, Inc. (MLYS) ha presentado un Formulario 144 indicando una venta planificada de 15,884 acciones ordinarias a través del corredor Merrill Lynch. Según el valor agregado de mercado declarado, la transacción está valorada en aproximadamente $230,430. Las acciones fueron adquiridas el 10/07/2025 mediante la consolidación de una adjudicación de unidades de acciones restringidas otorgadas bajo el plan de compensación accionaria de la empresa y se espera que se vendan en o después del 11/07/2025 en el NASDAQ.

La presentación muestra 65,175,287 acciones en circulación; por lo tanto, la venta propuesta representa aproximadamente el 0.02 % del total de acciones. No se han producido otras ventas por parte del declarante en los últimos tres meses y no se afirmó ninguna información adversa material en la sección de certificación.

Mineralys Therapeutics, Inc. (MLYS)가 Form 144를 제출했습니다 이는 Merrill Lynch 중개인을 통해 15,884 보통주를 판매할 계획임을 나타냅니다. 명시된 총 시장 가치를 기준으로 거래 가치는 약 $230,430입니다. 해당 주식은 회사의 주식 보상 계획에 따라 부여된 제한 주식 단위 보상의 권리 확정으로 2025년 7월 10일에 취득되었으며, 2025년 7월 11일 이후 NASDAQ에서 매각될 예정입니다.

제출서류에는 65,175,287주 발행 주식이 명시되어 있으며, 제안된 매각은 전체 주식의 약 0.02%에 해당합니다. 제출자는 지난 3개월 동안 다른 매각을 하지 않았으며, 인증 섹션에서 중요한 부정적 정보는 없다고 명시했습니다.

Mineralys Therapeutics, Inc. (MLYS) a déposé un formulaire 144 indiquant la vente prévue de 15 884 actions ordinaires via le courtier Merrill Lynch. Sur la base de la valeur marchande agrégée indiquée, la transaction est estimée à environ 230 430 $. Les actions ont été acquises le 10/07/2025 par la levée d’une attribution d’unités d’actions restreintes accordée dans le cadre du plan de rémunération en actions de la société et devraient être vendues à partir du 11/07/2025 sur le NASDAQ.

Le dépôt indique 65 175 287 actions en circulation ; la vente proposée représente donc environ 0,02 % du total des actions. Aucun autre vente n’a été réalisée par le déclarant au cours des trois derniers mois, et aucune information défavorable significative n’a été mentionnée dans la section de certification.

Mineralys Therapeutics, Inc. (MLYS) hat ein Formular 144 eingereicht, das einen geplanten Verkauf von 15.884 Stammaktien über den Broker Merrill Lynch anzeigt. Basierend auf dem angegebenen Gesamtmarktwert wird die Transaktion auf ungefähr 230.430 $ geschätzt. Die Aktien wurden am 10.07.2025 durch die Ausübung einer Restricted Stock Unit-Zuteilung erworben, die im Rahmen des Aktienvergütungsplans des Unternehmens gewährt wurde, und sollen am oder nach dem 11.07.2025 an der NASDAQ verkauft werden.

Die Einreichung zeigt 65.175.287 ausstehende Aktien; der vorgeschlagene Verkauf entspricht somit etwa 0,02 % der Gesamtaktien. In den letzten drei Monaten gab es keine weiteren Verkäufe durch den Melder, und im Zertifizierungsabschnitt wurden keine wesentlichen negativen Informationen angegeben.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small insider sale (~0.02 % of float) via RSU vesting; minimal market impact expected.

The Form 144 discloses a routine disposition of 15,884 shares valued at about $230k, stemming from equity compensation. Relative to the 65.2 million shares outstanding, the transaction is immaterial and unlikely to influence supply-demand dynamics or investor sentiment in a meaningful way. The absence of prior sales in the last three months further limits signaling value. Overall, the filing is informational rather than impactful.

Mineralys Therapeutics, Inc. (MLYS) ha presentato un modulo 144 indicando la prevista vendita di 15.884 azioni ordinarie tramite il broker Merrill Lynch. In base al valore di mercato complessivo dichiarato, l’operazione è valutata approssimativamente 230.430 $. Le azioni sono state acquisite il 10/07/2025 tramite la maturazione di un premio in azioni vincolate concesso nell’ambito del piano di compensazione azionaria della società e si prevede che vengano vendute il o dopo il 11/07/2025 sul NASDAQ.

La comunicazione riporta 65.175.287 azioni in circolazione; la vendita proposta rappresenta quindi circa lo 0,02 % del totale delle azioni. Negli ultimi tre mesi non sono state effettuate altre vendite da parte del dichiarante e nella sezione di certificazione non sono state riportate informazioni negative rilevanti.

Mineralys Therapeutics, Inc. (MLYS) ha presentado un Formulario 144 indicando una venta planificada de 15,884 acciones ordinarias a través del corredor Merrill Lynch. Según el valor agregado de mercado declarado, la transacción está valorada en aproximadamente $230,430. Las acciones fueron adquiridas el 10/07/2025 mediante la consolidación de una adjudicación de unidades de acciones restringidas otorgadas bajo el plan de compensación accionaria de la empresa y se espera que se vendan en o después del 11/07/2025 en el NASDAQ.

La presentación muestra 65,175,287 acciones en circulación; por lo tanto, la venta propuesta representa aproximadamente el 0.02 % del total de acciones. No se han producido otras ventas por parte del declarante en los últimos tres meses y no se afirmó ninguna información adversa material en la sección de certificación.

Mineralys Therapeutics, Inc. (MLYS)가 Form 144를 제출했습니다 이는 Merrill Lynch 중개인을 통해 15,884 보통주를 판매할 계획임을 나타냅니다. 명시된 총 시장 가치를 기준으로 거래 가치는 약 $230,430입니다. 해당 주식은 회사의 주식 보상 계획에 따라 부여된 제한 주식 단위 보상의 권리 확정으로 2025년 7월 10일에 취득되었으며, 2025년 7월 11일 이후 NASDAQ에서 매각될 예정입니다.

제출서류에는 65,175,287주 발행 주식이 명시되어 있으며, 제안된 매각은 전체 주식의 약 0.02%에 해당합니다. 제출자는 지난 3개월 동안 다른 매각을 하지 않았으며, 인증 섹션에서 중요한 부정적 정보는 없다고 명시했습니다.

Mineralys Therapeutics, Inc. (MLYS) a déposé un formulaire 144 indiquant la vente prévue de 15 884 actions ordinaires via le courtier Merrill Lynch. Sur la base de la valeur marchande agrégée indiquée, la transaction est estimée à environ 230 430 $. Les actions ont été acquises le 10/07/2025 par la levée d’une attribution d’unités d’actions restreintes accordée dans le cadre du plan de rémunération en actions de la société et devraient être vendues à partir du 11/07/2025 sur le NASDAQ.

Le dépôt indique 65 175 287 actions en circulation ; la vente proposée représente donc environ 0,02 % du total des actions. Aucun autre vente n’a été réalisée par le déclarant au cours des trois derniers mois, et aucune information défavorable significative n’a été mentionnée dans la section de certification.

Mineralys Therapeutics, Inc. (MLYS) hat ein Formular 144 eingereicht, das einen geplanten Verkauf von 15.884 Stammaktien über den Broker Merrill Lynch anzeigt. Basierend auf dem angegebenen Gesamtmarktwert wird die Transaktion auf ungefähr 230.430 $ geschätzt. Die Aktien wurden am 10.07.2025 durch die Ausübung einer Restricted Stock Unit-Zuteilung erworben, die im Rahmen des Aktienvergütungsplans des Unternehmens gewährt wurde, und sollen am oder nach dem 11.07.2025 an der NASDAQ verkauft werden.

Die Einreichung zeigt 65.175.287 ausstehende Aktien; der vorgeschlagene Verkauf entspricht somit etwa 0,02 % der Gesamtaktien. In den letzten drei Monaten gab es keine weiteren Verkäufe durch den Melder, und im Zertifizierungsabschnitt wurden keine wesentlichen negativen Informationen angegeben.

Filed Pursuant to Rule 424(b)(5)
Registration No. 333-286954

AMENDMENT NO. 1 DATED JULY 11, 2025

To Prospectus Dated May 15, 2025

 

LOGO

 

 

I-MAB

Up to $50,000,000

 

 

American Depositary Shares representing Ordinary Shares

This Amendment No. 1 to Prospectus (this “Amendment”) amends our prospectus, dated May 15, 2025 (the “Prospectus”), relating to the offer and sale of up to $21,000,000 of our American Depositary Shares (“ADSs”), each ten (10) ADSs representing twenty-three (23) ordinary shares, par value $0.0001 per share. This Amendment should be read in conjunction with the Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus. This Amendment is not complete without, and may only be delivered or utilized in connection with, the Prospectus and any future amendments or supplements thereto.

We previously entered into a sales agreement, dated May 2, 2025 (the “Sales Agreement”), with Leerink Partners LLC (“Leerink Partners”), relating to the sale of our ADSs. As of the date of this Amendment, we have not sold any ADSs pursuant to the Sales Agreement and the Prospectus.

We are no longer subject to the General Instruction I.B.5 of Form F-3 as the aggregate market value of our ordinary shares (including ordinary shares represented by ADSs) held by non-affiliates equaled or exceeded $75.0 million as of June 9, 2025. Accordingly, we are filing this Amendment to update the maximum amount of ADSs that we are eligible to sell under the Prospectus. Following this Amendment, we may offer and sell ADSs having an aggregate offering price of up to $50,000,000 pursuant to this Amendment and the Prospectus in accordance with the terms of the Sales Agreement.

Our ADSs are currently listed on the Nasdaq Global Market (“Nasdaq”) under the symbol “IMAB”. On July 10, 2025, the last reported sales price of the ADSs on Nasdaq was $2.05 per ADS.

 

 

Investing in our securities involves risks. You should carefully consider the risks and uncertainties described under the heading “Risk Factors” on page 8 of the Prospectus and in the documents that are incorporated by reference into this Amendment and the Prospectus.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS SUPPLEMENT AND ACCOMPANYING PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

 

 

Leerink Partners

 

 

The date of this Amendment No. 1 to Prospectus is July 11, 2025.

FAQ

How many Mineralys Therapeutics (MLYS) shares are being sold under the Form 144?

The notice covers 15,884 common shares.

What is the approximate market value of the proposed share sale?

The aggregate market value is stated as $230,430.05.

When is the expected sale date for the MLYS shares?

The filing lists an approximate sale date of 07/11/2025.

How were the shares to be sold acquired?

They were obtained on 07/10/2025 through the vesting of a restricted stock unit award granted under the company’s equity plan.

What percentage of Mineralys Therapeutics’ outstanding shares does the sale represent?

With 65,175,287 shares outstanding, the 15,884-share sale equals roughly 0.02 % of total shares.

Which broker is handling the transaction?

The shares will be sold through Merrill Lynch, 225 Liberty St, New York, NY 10281.

Were any other shares sold by the filer in the past three months?

No. The filing states "Nothing to Report" for prior 3-month sales.
I-Mab

NASDAQ:IMAB

IMAB Rankings

IMAB Latest News

IMAB Latest SEC Filings

IMAB Stock Data

170.67M
58.25M
11.16%
33.33%
1.09%
Biotechnology
Healthcare
Link
United States
Rockville